Nycomed to market Norgine's laxative MoviPrep in Russia and CIS

Swiss independent drugmaker Nycomed and Netherlands-headquartered Norgine, have entered into a licensing agreement that gives Nycomed (which is in the throes of being acquired by Japan’s Takeda) the exclusive rights to commercialize MoviPrep, a leading bowel cleansing brand, in Russia and the Commonwealth of Independent States (comprising Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan).

Financial terms of the deal were not revealed. MoviPrep will be subject to regulatory review and approval and Nycomed will conduct the necessary steps for gaining market clearances.

MoviPrep is an osmotic laxative for bowel cleansing prior to any clinical procedure requiring a clean bowel, such as colonoscopy. It is a laxative solution that increases the amount of water in the intestinal tract to stimulate bowel movements and contains potassium, sodium and other minerals to replace electrolytes that are passed from the body in the stool.